Appl. No.

10/657,022

Filed

September 5, 2003

AMENDMENTS TO THE SPECIFICATION

Please amend Paragraph [0057] as follows:

Figures 1A-C show is-a sequence alignment of NY-ESO-1 (SEQ ID NO: 611) and several similar protein sequences; AADO5202-CAG-3 (SEQ ID NO: 612), CAA11044-LAGE-1a (SEQ ID NO: 613), CAA10194-LAGE1s (SEQ ID NO: 614), CAA11043-LAGE1b (SEQ ID NO: 615), CAA10196-LAGE1L (SEQ ID NO: 616), AAH02883 CT-2 (SEQ ID NO: 617) and the consensus sequence (SEQ ID NO: 618).

Please amend Paragraph [0064] as follows:

<u>Figures</u> Figure 7A, B, and C show results of N-terminal pool sequencing of a T=60 min. time point aliquot of the PSMA₁₆₃₋₁₉₂ (SEQ ID NO: 619) proteasomal digest.

Please amend Paragraph [0066] as follows:

Figure 9 shows results of N-terminal pool sequencing of a T=60 min. time point aliquot of the PSMA₂₈₁₋₃₁₀ (SEQ ID NO: 620) proteasomal digest.

Please amend Paragraph [0075] as follows:

Figures 18-70 (SEQ ID NOS: 621-673, respectively) are proteasomal digestion maps depicting the mapping of mass spectrum peaks from the digest onto the sequence of the indicated substrate.

Please amend Table 4 as follows (please note that the new column with the heading "SEQ ID NO:" has been added to the table. The title of the table, despite being underlined, has not been amended):

Table 4. SSX-2₃₁₋₆₈ Mass Peak Identification.

MS PEAK	PEPTIDE	SEQ ID	SEQUENCE	CALCULATED
(measured)		NO:		MASS (MH ⁺)
988.23	31-37	<u>674</u>	YFSKEEW	989.08
1377.68±2.3		<u>675</u>		
8	31-40		YFSKEEWEKM	1377.68
1662.45±1.3		<u>676</u>		
0	31-43		YFSKEEWEKMKAS	1663.90
2181.72±0.8		677		
5	31-47		YFSKEEWEKMKASEKIF	2181.52
2346.6	31-48	<u>678</u>	YFSKEEWEKMKASEKIFY	2344.71

Appl. No.

10/657,022

September 5, 2003 **Filed**

1472.16±1.5		679	,	
4	38-49		EKMKASEKIFYV	1473.77
2445.78±1.1		680		
8	31-49*		YFSKEEWEKMKASEKIFYV	2443.84
2607.	31-50	681	YFSKEEWEKMKASEKIFYVY	2607.02
1563.3	50-61	682	YMKRKYEAMTKL	1562.93
3989.9	31-61	683	YFSKEEWEKMKASEKIFYVYMKRKYEAMTKL	3987.77
1603.74±1.5		684		
3	51-63		MKRKYEAMTKLGF	1603.98
		685		
1766.45±1.5	50-63		YMKR KYEAMTKLGF	1767.16
1866.32±1.2		686		
2	49-63		VYMKRKYEAMTKLGF	1866.29
		687	YFSKEEWEKMKASEKIFYVYMKRKYEAMTKLG	-
4192.6	31-63		F	4192.00
		688	YFSKEEWEKMKASEKIFYVYMKRKYEAMTKLG	•
4392.1	31-65**		FKA .	4391.25

Please amend Paragraph [0252] as follows:

HLA-A*0201 binding studies were preformed with PSMA₁₆₈₋₁₇₇, GMPEGDLVYV, (SEQ ID NO. 33) (SEQ ID NO: 33) essentially as described in Example 3 above. As seen in figure 8, this epitope exhibits significant binding at even lower concentrations than the positive control peptides. The Melan-A peptide used as a control in this assay (and throughout this disclosure), ELAGIGILTV (SEQ ID NO: 689), is actually a variant of the natural sequence (EAAGIGILTV (SEQ ID NO: 690)) and exhibits a high affinity in this assay.